Last reviewed · How we verify

Aduro Biotech, Inc. — Portfolio Competitive Intelligence Brief

Aduro Biotech, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aeras · 1 shared drug class
  2. Aga Khan University · 1 shared drug class
  3. Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
  4. Alba Maria Ropero · 1 shared drug class
  5. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  6. Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aduro Biotech, Inc.:

Cite this brief

Drug Landscape (2026). Aduro Biotech, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aduro-biotech-inc. Accessed 2026-05-16.

Related